Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Herman W. Powery"'
Publikováno v:
Journal of Clinical Oncology. 39:e20531-e20531
e20531 Background: The PACIFIC trial demonstrated that durvalumab improved 3-year overall survival in unresectable Stage III non-small-cell lung cancer (NSCLC) following chemoradiotherapy (CRT). However, there is no consensus on the preferred therapy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5a97260c9608d2fa8d910188d65aa0f4
https://doi.org/10.1200/jco.2021.39.15_suppl.e20531
https://doi.org/10.1200/jco.2021.39.15_suppl.e20531
Publikováno v:
Journal of Clinical Oncology. 39:e21044-e21044
e21044 Background: Overweight and obesity have been associated with improved overall survival (OS) and progression-free survival (PFS) in patients treated with immune checkpoint inhibitors (ICI). EPSILoN score (EPSILoN), comprised of five clinical va
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0c54a41057a5c9f8af3f53bec34302a3
https://doi.org/10.1200/jco.2021.39.15_suppl.e21044
https://doi.org/10.1200/jco.2021.39.15_suppl.e21044
Autor:
Luis E. Raez, Alejandro Lopez-Cohen, Herman W. Powery, Leylah Drusbosky, Hiba I. Dada, Delia A Wietecha, Paola Izquierdo, Kayla Brice, Katerine Dumais
Publikováno v:
Journal of Clinical Oncology. 39:e21103-e21103
e21103 Background: Current literature has demonstrated non-inferiority of liquid biopsies relative to tissue genotyping to identify detectable biomarkers in patients with metastatic non-small cell lung cancer (NSCLC). However, liquid biopsies have th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::34f16a02dbebfe6f11d312aa2ef99c1c
https://doi.org/10.1200/jco.2021.39.15_suppl.e21103
https://doi.org/10.1200/jco.2021.39.15_suppl.e21103
Autor:
Frank Gentile, Katerine Dumais, Paola Izquierdo, Gelenis Calzadilla Domingo, Brian Hunis, Luis E. Raez, Herman W. Powery, Richie Uba
Publikováno v:
Journal of Clinical Oncology. 38:e15055-e15055
e15055 Background: There is immune evasion and resistance to checkpoint inhibitors (CPI). Programmed death-ligand 1 (PD-L1) and Tumor mutational burden (TMB) might help us predict response, but we have not yet validated biomarkers that can predict re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9385fcad2e04ffe82d88765b11c86b3c
https://doi.org/10.1200/jco.2020.38.15_suppl.e15055
https://doi.org/10.1200/jco.2020.38.15_suppl.e15055
Autor:
Luis E. Raez, Teresita Muñoz-Antonia, Scott J. Antonia, Martin F. Dietrich, Daniel Sumarriva, W. Douglas Cress, Herman W. Powery, Brian Hunis, Paola Izquierdo, Alberto Chiappori
Publikováno v:
Journal of Clinical Oncology. 36:e18665-e18665
e18665Background: Hispanics (H) in the US seem to have a lower age-adjusted mortality resulting from non-small cell lung cancer (NSCLC) compared with Non-Hispanic Whites (NHW). Immunotherapy outcom...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::74a91f1474a187d9280b2273c5d3cae9
https://doi.org/10.1200/jco.2018.36.15_suppl.e18665
https://doi.org/10.1200/jco.2018.36.15_suppl.e18665